Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
0.5350
-0.0065 (-1.20%)
Feb 11, 2026, 4:00 PM EST - Market closed

Xilio Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Feb '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
36421574437-
Market Cap Growth
11.13%177.26%-79.46%-83.14%--
Enterprise Value
-60-11-30-45581-
Last Close Price
0.540.950.552.6916.00-
PS Ratio
0.876.62----
PB Ratio
-2.380.410.702.36-
P/TBV Ratio
-2.380.410.702.36-
Debt / Equity Ratio
-0.900.460.340.190.11-4.14
Asset Turnover
0.310.10----
Quick Ratio
2.152.102.805.7015.500.87
Current Ratio
2.202.213.025.9015.850.93
Return on Equity (ROE)
-908.29%-214.02%-107.25%-60.62%-84.16%-332.22%
Return on Assets (ROA)
-26.26%-56.48%-49.44%-31.20%-36.88%-68.86%
Return on Capital Employed (ROCE)
-56.60%-136.10%-176.00%-75.50%-36.60%-385.30%
Earnings Yield
-161.87%-138.74%-504.62%-119.66%-17.33%-
FCF Yield
-48.65%-43.86%-456.42%-105.24%-18.72%-
Buyback Yield / Dilution
-17.23%-94.62%-0.38%-388.59%-970.34%-27.97%
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q